CoronaVac vaccine safe and effective in older age groups

China // 04 February, 2021

Results from the Phase 1/2 clinical trial of the CoronaVac vaccine in elderly people have been published in the Lancet. This is the COVID-19 vaccine developed in China by Sinovac Biotech, and is already being administered in several countries including China, Indonesia and Turkey.

Over 420 people aged 60 years and older were enrolled into the study in Hebei province, China, in May and June 2020. More than 95% of people receiving both shots of the 3μg or 6μg doses developed antibodies, which is comparable to the results for adults aged 18-59 years. There were no safety concerns in this older age group either.

The authors conclude that “CoronaVac is safe and well tolerated in older adults” and that the 3μg dose of the vaccine should be further investigated in Phase 3 clinical trials in older age groups.

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …